The functional relevance of the B-cell receptor (BCR) and the evolution of protein kinases as therapeutic targets have recently shifted the paradigm for treatment of B-cell malignancies. Inhibition of p110δ with idelalisib has shown clinical activity in chronic lymphocytic leukemia (CLL). The dynamic interplay of isoforms p110δ and p110γ in leukocytes support the hypothesis that dual blockade may provide a therapeutic benefit. IPI-145, an oral inhibitor of p110δ and p110γ isoforms, sensitizes BCR-stimulated and/ or stromal co-cultured primary CLL cells to apoptosis (median 20%, n = 57; Po 0.0001) including samples with poor prognostic markers, unmutated IgVH (n = 28) and prior treatment (n = 15; P o 0.0001). IPI-145 potently inhibits the CD40L/IL-2/IL-10 induced proliferation of CLL cells with an IC 50 in sub-nanomolar range. A corresponding dose-responsive inhibition of pAKT Ser473 is observed with an IC 50 of 0.36 nM. IPI-145 diminishes the BCR-induced chemokines CCL3 and CCL4 secretion to 17% and 37%, respectively. Pre-treatment with 1 μM IPI-145 inhibits the chemotaxis toward CXCL12; reduces pseudoemperipolesis to median 50%, inferring its ability to interfere with homing capabilities of CLL cells. BCR-activated signaling proteins AKT Ser473 , BAD Ser112 , ERK Thr202/Tyr204 and S6 Ser235/236 are mitigated by IPI-145. Importantly, for clinical development in hematological malignancies, IPI-145 is selective to CLL B cells, sparing normal B-and T-lymphocytes.
INTRODUCTION
For many years, chemo-immunotherapy has been the standard of care for chronic lymphocytic leukemia (CLL). 1 However, association with a variety of morbidities, including secondary malignancies has been a major drawback with conventional chemotherapies. The functional relevance of the B-cell receptor (BCR) pathway and the identification of protein and lipid kinases as therapeutic targets have recently shifted the paradigm for treatment of B-cell malignancies. Inhibitors of Bruton's tyrosine kinase and phosphatidylinositide-3-kinase (PI3K)-delta, ibrutinib and idelalisib, have shown promising activity in the clinic and are recently Food and Drug Administration approved for CLL. 2, 3 Of the three classes of PI3K isoforms, class IA comprises the p110α, p110β and p110δ catalytic domains and class IB is made up uniquely of the p110γ. 4 These catalytic domains partner with p85 or p101/p84 regulatory subunits to make the holoenzymes that phosphorylate phosphatidylinositol (4,5)-bisphosphate (PIP 2 ) to phosphatidylinositol (3,4,5)-trisphosphate (PIP 3 ); reversal of this reaction is catalyzed by a phosphatase and tensin homolog. 5 As PI3K and phosphatase and tensin homolog are among the most frequently mutated oncogene and tumor-suppressor gene in solid tumors, this pathway has become a desired axis to target. 6 In B-cell malignancies, although this pathway is not commonly mutated, the differential expression and function of p110 isoforms in BCR signaling provide the potential for targeted therapeutic intervention. Whether PI3K isoform-specific or pan-isoform PI3K inhibition constitutes the optimal therapeutic strategy in lymphoid malignancies is still under debate. However, the distinct role of the p110γ and p110δ support isoform-specific inhibition in B-cell malignancies. 7 P110δ is a key isoform for B cells as it has a crucial role in mediating BCR signaling, proliferation/survival, antibody production and/or antigen presentation. 8 It is vital for B-and T-cell activation and function, 9 Fc receptor signaling in mast cells, 10 Th1-Th2 differentiation 11 and T-regulatory cell function. 12 Although p110γ is expressed in CLL, 13 there is less evidence for the role of p110γ than for p110δ in the regulation of B-cell activation and/or function. However, studies highlight a critical function of p110γ in leukocyte chemotaxis, 14 mast cell activation, chemokine-mediated trafficking and microglial activation. 15 Isoform p110γ is integral to the integrin-dependent homing of progenitor cells and compounds reported to inhibit p110γ significantly reduced the CXCL12 (SDF-1α)-induced transmigration of human epithelial cells. 16 It is reported that p110γ is indispensable for constitutive migration of naive CD8 T cells and subsequent activation and differentiation into effector CD8 T cells, and their migration to inflammatory sites. 17 Dendritic cells obtained from p110γ-deficient mice showed a reduced ability to respond to chemokines or to migrate to lymph node sites. 18 Studies in mice either lacking p110δ or p110γ reported that p110γ-deficient T cells but not B cells showed reduced chemotactic responses to the lymphoid chemokines, CCL19, CCL21 and CXCL12. In contrast, p110δ-deficient B cells showed a diminished chemotactic response to CXCL13. Together, these data establish the distinct roles of p110δ and p110γ in lymphocyte function and immune cell trafficking.
Clinical studies have demonstrated that inhibition of p110δ isoform has therapeutic value for CLL patients. 2, 19, 20 Given the multiple roles of p110δ and p110γ isoforms in lymphocyte function and their combined activity in mediating efficient trafficking of immune competent cells, we hypothesized that the dual blockade of isoforms p110δ and p110γ could present a unique therapeutic opportunity in the treatment of B-cell malignancies. IPI-145 is an orally bioavailable, highly potent small-molecule inhibitor of p110δ and p110γ with K D values of 0.023 and 0.24 nM, respectively. 21, 22 Importantly, inhibition of both isoforms is observed at physiologically relevant concentrations. IPI-145 has profound effects on adaptive and innate immunity inhibiting B-and T-cell proliferation, blocking neutrophil migration, inhibiting basophil activation and showed activity in collagen-induced arthritis, ovalbumin-induced asthma and systemic lupus erythematosus rodent models. Inhibition of neutrophil and eosinophil recruitment and cytokine production in an asthma model was observed with doses of IPI-145 sufficient to block p110γ, but less so with lower doses predicted to inhibit only p110δ. 21 In addition, phase 1 studies in hematologic malignancies with IPI-145 (Duvelisib) have shown clinical activity in indolent non-Hodgkin lymphoma and CLL, and phase 2 and phase 3 studies in these indications are currently underway. [23] [24] [25] [26] [27] [28] With accumulating evidence that CLL disease is dependent on interactions with the immune microenvironment, the effect of combined inhibition of p110δ and p110γ isoforms with IPI-145 was investigated in primary CLL cells. These data complement previous reports on the biological consequences and molecular changes in primary CLL cells induced by isoform-specific inhibition. 29, 30 IPI-145 showed direct cytotoxicity; cytokinemediated induction of CLL cell proliferation was markedly reduced. Inhibition of BCR signaling, reflected by decreased activation of AKT, BAD, ERK and S6, downstream markers of an active PI3K signaling pathway was observed. IgM-stimulated induction of chemokines, such as CCL3 and CCL4, was mitigated by IPI-145 in primary samples. Furthermore, CLL cell chemotaxis and migration were diminished by IPI-145, implicating multiple roles of p110δ and p110γ isoforms in survival, lymphocyte trafficking and cell migration in B-cell malignancies.
PATIENTS AND METHODS

Drugs and chemicals
IPI-145, idelalisib and ibrutinib for in vitro use were provided by Infinity Pharmaceuticals, Inc., Cambridge, MA, USA. 21 Dimethyl sulfoxide was purchased from Sigma-Aldrich (St Louis, MO, USA). The final concentration of dimethyl sulfoxide in control and treated cultures was 0.1%. Anti-IgM (polyclonal goat F(ab')2 fragments to human IgM) was obtained from MP Biomedicals (Santa Ana, CA, USA) or from Jackson Immunoresearch (West Grove, PA, USA). CXCL12 (SDF-1α) for chemotaxis experiments (200 ng/ml) was obtained from R&D Systems (Minneapolis, MN, USA). sCD40L and IL-10 were purchased from Life Technologies (Grand Island, NY, USA) and IL-2 was from Peprotech (Rocky Hill, NJ, USA). For FACScan, PerCP anti-human CD19 and CD5-PE were obtained from Biolegend (San Diego, CA, USA). Alexa Fluor 488 anti-human Ki67 and pAKT (Ser 473 ) (D9E) XP (Alexa Fluor 647) were purchased from BD Biosciences (San Jose, CA, USA) and Cell Signaling (Danvers, MA, USA), respectively.
Patients and healthy donors
This study was carried out using lymphocytes isolated from peripheral blood samples obtained from healthy donors or patients with CLL. 31 All participants signed written informed consent forms in accordance with the Declaration of Helsinki, and the laboratory protocols were approved by the Institutional Review Board at the University of Texas MD Anderson Cancer Center.
Isolation of leukemia cells
CLL or normal peripheral blood mononuclear cells (PBMCs) were isolated from peripheral blood samples by Ficoll-hypaque procedure and plated at a density of 1 × 10 7 cells/ml in RPMI medium+10% autologous plasma. 31 BCR triggering and marrow stromal cell (MSC) co-culture CLL samples were pre-incubated in RPMI medium (containing 10% autologous plasma), stimulated with 10 μg/ml α-IgM and incubated without or with IPI-145. 32 For co-culture studies, CLL lymphocytes were cultured with or without confluent layers of human MSC (NKtert; RIKEN cell bank, Tsukuba, Japan) at a ratio of 100 CLL cells to 1 MSC. 31 The NKTert cell line was maintained and routinely tested for Mycoplasma infection and authenticated by short tandem repeat analysis at MD Anderson Cancer Center's characterized cell line core facility.
Measurement of cell viability
Cell viability was measured by the standard method of AnnexinV/PIbinding assay. 31 Chemokine quantification CCL3 and CCL4 concentrations in cell culture supernatants of α-IgMstimulated CLL cells and/or stromal co-cultured CLL cells were measured in the absence or presence of IPI-145 using Quantikine ELISA kits (R&D Systems) according to the manufacturer's protocol. 32 A standard curve containing a blank was prepared for each experiment in the absence of chemokines, and its absorbance was subtracted from that obtained in the presence of sample. Results were expressed as concentration in pg/ml for each sample.
Chemotaxis toward CXCL12 (SDF-1α)
Chemotaxis assays across polycarbonate transwell inserts were performed as previously described. 32 Briefly, 10 million cells were incubated in RPMI medium (containing 10% autologous plasma) in the absence or presence of 1 μM IPI-145 for 1 h and transferred into the top chambers of Transwell cell culture inserts (Costar, Sigma-Aldrich) with a diameter of 6.5 mm and a pore size of 5 μm. Filters were placed onto wells containing medium (control) or medium with 200 ng/ml CXCL12 (SDF-1α) (R&D Systems), and CLL cells were allowed to migrate for 3 h at 37°C. Migrated cells in the lower chamber were collected and counted on a FACSCalibur for 20 s at 60 μl/min in duplicates.
Migration beneath MSCs (pseudoemperipolesis)
NKTert stromal cells were seeded the day before the assay onto collagencoated 12-well plates at 5 × 10 4 cells per well. Next day, 10 7 CLL cells/ml were incubated for 4 h with or without IPI-145. Cells that had not migrated into the stromal cell layer were removed by vigorously washing with RPMI medium and the stromal cell layer containing transmigrated cells was detached by incubation for 1 min with trypsin/EDTA. Cells were immediately resuspended and counted by FACSCalibur for 20 s at 60 μl/min in duplicate as described previously. 33 A lymphocyte gate was set according to the different relative size and granularity (forward scatter and side scatter) characteristics to exclude stromal cells from the counts.
Proliferation of CLL cells and AKT activation
CLL PBMCs were seeded at 1 × 10 6 cells per well in a 24-well plate and treated with either 10 μg/ml IgM or a cytokine cocktail containing 1 μg/ml sCD40L, 10 ng/ml IL-10 and 10 ng/ml IL-2. Cells were harvested at various time points after stimulation, fixed in BD Cytofix Fixation Buffer and stored at -80°C for subsequent flow cytometry analyses. Untreated samples were collected at every time point as baseline controls. For CLL proliferation assays, cells were treated with the cytokine cocktail and harvested 5 days later. For both assays, intracellular expression of Ki67 and pAKT Ser473 were measured in CD19 + /5 + CLL cells by flow cytometry.
Immunoblot analysis
CLL cell pellets were washed with phosphate-buffered saline, lysed on ice for 20 min in RIPA lysis buffer and the supernatant was removed and the protein content was determined using a DC protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA), loaded and transferred to nitrocellulose membranes (GE Osmonics Labstore, Minnetonka, MN, USA) as described previously. 31 Membranes were blocked for 1 h in licor blocking buffer, incubated with primary antibodies overnight at 4°C against the following: pAKT(Ser 473 ), t-AKT, pERK (Thr 202 /Tyr 204 ), t-ERK (Cell Signaling), p-Bad, t-Bad, p-S6, t-S6, Mcl-1, Bcl-xL, Bcl-2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and GAPDH (Abcam, Cambridge, MA, USA). The antibodies to poly (ADP-ribose) polymerase (PARP) was from BIOMOL International (Plymouth Meeting, PA, USA), and PI3K isoforms were from EMD Millipore (Billerica, MA, USA). After washing with phosphate-buffered saline-Tween-20, membranes were incubated with infrared-labeled secondary antibodies (LI-COR Inc., Lincoln, NE, USA) for 1 h, scanned and visualized using LI-COR Odyssey Infrared Imager.
Statistical analysis
Linear regression analysis and Student's t-tests (two tailed) were performed using the GraphPad Prism6 software (GraphPad Software, Inc., San Diego, CA, USA).
RESULTS
IPI-145 abrogates BCR-mediated and bone marrow stromal cellmediated survival in primary CLL cells
The effect of IPI-145 (structure- Figure 1a ), on BCR-and MSCmediated cell survival was determined. As expected, α-IgM crosslinking induced an increase in viability (median 90%, range 66-98%) in comparison with unstimulated CLL cells (median 85%, range 39-97%; n = 19; Figure 1b ; Po0.0001; 24 h). Of note, samples with 17p deletion demonstrated high viability in cultures under unstimulated conditions (n = 7; Table 1 ). Incubation with 1 μM IPI-145 significantly reduced CLL cell viability to a median 80% (range 31-96%) in BCR-stimulated cells. Although there was heterogeneity in response to IPI-145 among various samples ( Figure 1b ; each symbol denotes a representative patient's sample), overall there was a moderate, yet significant decrease in viability of samples analyzed by a paired Student's t-test (controls are normalized to 100%; Figure 1c ; Po0.0001; n = 19). As has been shown previously, stromal co-cultures increased viability of CLL cells (median 95%, range 69-98%) in comparison with primary cells with no stromal support (median 80%; range 39-95%; Figure 1d ; n = 20). Incubation of co-culture samples with 1 μM IPI-145 for 24 h significantly reduced CLL cell viability to a median of 73% (range 42-96%, Figure 1d ; Po0.0001; n = 20). A list of patient samples (n = 57), their prognostic factors and percent viability of CLL cells without or with IPI-145 in BCR-stimulated and/or stromal co-cultured model systems is provided (Table 1) Figure 3B ).
Correlative response of IPI-145 with prognostic factors
Given the heterogeneity among samples, subgroup analyses were performed on established genetic subtypes of CLL ( Figure 1e ). Samples with 11pdel (n = 6), 13qdel (n = 19), trisomy 12 (n = 6) and 17pdel (n = 9) were equally sensitive to IPI-145 (P o0.0001).
IgM
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Inhibition of CCL3 and CCL4 chemokine secretion
In response to BCR activation by α-IgM stimulation, there was a robust increase in the production of chemokines CCL3 (n = 11) and CCL4 (n = 5) in the cell culture supernatants (Figures 3a and b) . The mean CCL3 and CCL4 concentrations in supernatants of CLL cells following α-IgM stimulation increased from 17 to 831 pg/ml and 347 to 2283 pg/ml, respectively (Figures 3a and b ; 24 h; P o0.0001). Treatment of CLL cells with 1 μM IPI-145 abrogated the BCR-induced production of CCL3 and CCL4 significantly, reducing the respective mean values to 142 and 840 pg/ml. To determine if the chemokine production is induced through interactions with bone marrow stromal microenvironment, the levels of CCL3 and CCL4 were measured in the supernatants of CLL cells co-cultured with supporting stromal cells. In contrast to BCR-stimulated cells, co-cultured CLL cells exhibited no significant change in chemokine production (Figure 3c ; n = 4 and D; n = 5; 24 h). These data suggest that the chemokine production is primarily mediated by BCR signaling and not through interactions with bone marrow stroma cells. These observations indicate a context-dependent production of chemokines, as previous studies showed that CLL cells co-cultured with nurse like cells (that represent a lymph node microenvironment) secreted significant levels of chemokines. 35 
Inhibition of CLL cell chemotaxis and migration beneath stromal cells by IPI-145
Given the pivotal role of PI3K in leukocyte trafficking, inhibition of chemotaxis toward CXCL12/SDF-1α was evaluated with IPI-145. Primary CLL cells incubated in transwell inserts (for 3 h at 37 o C) in media containing CXCL12 demonstrated an increase in migration toward CXCL12 to a median 2863 cells per 20 s (range 851-3649 counts) in comparison with control, median 612 (range 215-2569 counts) (Figure 4a ; n = 8). However, pre-treatment with 1 μM IPI-145 significantly inhibited the chemotaxis toward CXCL12 to a median of 2142 cells per 20 s (range 788-3572 counts); (Figure 4a) . Similarly, migration of CLL cells beneath the MSCs (pseudoemperipolesis) was diminished by 1 μM IPI-145 (median 50%; range 6-70%) in comparison with control (normalized to 100%) inferring that IPI-145 potently interferes with the homing and migration capabilities of CLL cells (Figure 4b ; n = 4).
Inhibition of BCR-and MSC-activated signaling molecules by IPI-145
Given that IPI-145 is a potent inhibitor of p110δ and p110γ isoforms, we tested the inhibition of signaling proteins downstream BCR pathway. for each patient). Pre-incubation with IPI-145 in BCR-activated cells did not reverse the inhibition of signaling axis or PARP cleavage (Figures 5c and e ; n = 6; lane 4 for each patient; pAKT-P = 0.006; pERK-P = 0.011; pBAD-P = 0.007). On the same note, quantitation of immunoblots of signaling molecules on co-cultured samples without and with IPI-145 revealed no statistical significance (Figures 5d and f; n = 3) , which could be due to variability in sample prognosis, in a small set of samples (n = 3). Finally, differential expression of PI3K isoforms was observed in primary CLL cells; with abundant p110δ and p110β, modest p110γ and undetectable levels of p110α in the samples tested (Figure 5g ; n = 3). α-IgM stimulation or IPI-145 treatment did not affect the protein levels of isoforms.
Comparative studies of IPI-145 with idelalisib and ibrutinib In addition to proliferation assays (Figure 2b) , studies were conducted to compare activities of IPI-145 with other BCR % Change pathway kinase inhibitors in apoptosis induction, migration inhibition and chemokine blockade. Comparison of IPI-145 to idelalisib and ibrutinib with respect to apoptosis induction (n = 35) revealed that at an equivalent concentration, all three inhibitors had similar levels of cytotoxicity (Figure 6a ; Po 0.0001; all three agents) for primary CLL cells. In addition, CLL cells stimulated with α-IgM (n = 11) and/or co-cultured with stromal cells (n = 7) in presence or absence of IPI-145, idelalisib and ibrutinib demonstrated statistically significant induction of apoptosis (Figure 6b ; IPI-145-P = 0.007; IDE-P = 0.009; IBR-P = 0.03) and (Figure 6c ; IPI-145-P = 0.001; IDE-P = 0.02; IBR-P = 0.05), respectively. Inhibition of chemokine production (Figure 6d ; n = 4) and migratory abilities of CLL cells (Figure 6e ; n = 4) tested at an equivalent concentration were P = 0.02; P = 0.11; P = 0.07 and P = 0.03; P = 0.09 and 0.33 for IPI-145, idelalisib and ibrutinib, respectively.
Effect of IPI-145 on normal PBMCs
To evaluate the therapeutic index, we investigated the effect of IPI-145 on PBMCs isolated from peripheral blood of normal donors at concentrations that decreased the viability of CLL cells (Figures 7a and b; n = 3; 1 μM; 24 h). The cytotoxicity assay using specific surface markers on the two lymphoid subsets revealed that IPI-145 is selective to CLL cells sparing normal T-and B-lymphocytes (Figure 7c ).
DISCUSSION
The BCR signaling pathway has a key role in the pathogenesis of CLL. The PI3Kδ that is downstream of BCR regulates several cellular processes. Class IA PI3K (isoforms p110α and p110β) that are universally expressed in all cell types, regulate cell cycle entry in controlling cell division, DNA replication, insulin metabolism and tumorigenesis. [36] [37] [38] [39] As p110δ is primarily restricted to leukocytes, drug development efforts have initially focused on synthesizing small-molecule inhibitors of p110δ for the treatment of B-cell malignancies. 35, [40] [41] [42] [43] Idelalisib (formerly called CAL-101 and GS-1101) is a potent, oral, selective small-molecule inhibitor of p110δ.
In phase 1 studies, idelalisib both as a single agent and in combination with rituximab had clinical activity with a generally acceptable toxicity profile in patients with lymphoma and relapsed or refractory CLL. 2, 19, 20, 44, 45 Idelalisib is approved by the US Food and Drug Administration for the treatment of patients It is also proposed to be involved in CLL because of its role in immune cell activation and trafficking via chemokines. [46] [47] [48] Our data demonstrated no cytotoxicity to CD3+ T-cell subsets with IPI-145 suggesting that the inhibition of gamma isoform with IPI-145 may have effect on specific T-cell subsets within microenvironment. IPI-145 is a potent inhibitor of p110δ and p110γ, (the isoforms predominantly expressed in immune cells) and is currently being investigated in hematological malignancies.
Cell death induction by IPI-145 is apparent in BCR-stimulated cells, as well as in CLL cells co-cultured with supporting stromal cells (Figure 1 ). Identification of potential novel biomarkers in response to PI3K inhibition is in progress. Of these, the leading candidates are chemokines CCL3 (ref. 49) and CCL4, secreted by both normal and malignant lymphocytes that act through the chemokine receptors CCR1 and CCR5. When the BCR pathway is activated, these chemokines are secreted in high levels by leukemic lymphocytes, particularly lymph node derived CLL cells. [50] [51] [52] Experiments with IPI-145 displayed substantial inhibition of both CCL3 and CCL4 production in BCR-stimulated assays (Figures 3a and b) . These chemokines are also among the chemokines and cytokines reduced in CLL patients receiving IPI-145. 53 Circulating CLL cells in peripheral blood are largely arrested in the G0/G1 phase of the cell cycle and undergo spontaneous apoptosis in vitro. However, heavy water labeling studies report a more significant amount of CLL B-cell proliferation in the pseudofollicles than was previously appreciated. 52, 54, 55 Both proliferation and resistance to apoptosis are believed to be governed by supporting stromal cells in the tissue microenvironment. Experiments with CLL cells and added chemokines that mimic the microenvironment to induce B-cell proliferation revealed the ability of IPI-145 to inhibit proliferation at low nM concentrations (Figures 2a and b) . In parallel to growth inhibition, there was a marked decrease in the phosphorylation of PI3K regulatory protein, AKT (Figure 2c ). Although apoptosis induction in peripheral blood-derived primary CLL cells was moderate (Figure 1a ), the effect of IPI-145 on cytokine-induced CLL cell proliferation was impressive. As tumor burden and proliferation in lymph nodes are strongly and directly associated with disease progression, 52 these results emphasize the potential clinical utility of IPI-145 in CLL.
The clinical activity of BCR pathway kinase inhibitors in patients with CLL is associated with marked lymphocytosis because of redistribution of tumor cells from the lymph node into the peripheral blood and/or because of disruption in the homing mechanisms of CLL cells. 20 Similar to other kinase inhibitors, IPI-145 inhibits the migration and chemotaxis of CLL cells in vitro, further supporting the significance of isoforms in the migration and homing capabilities of CLL cells (Figures 4a and b) .
IPI-145 is distinct from idelalisib, as it is an inhibitor of both p110δ and p110γ isoforms. Phase 1 dose-escalation study of IPI-145 with dose expansion cohorts including CLL patients reported that IPI-145 is generally well tolerated in patients with hematological malignancies and clinical activity is observed at all dose levels. In CLL, including high-risk patients, responses are seen with rapid resolution of lymphocytosis, justifying its further development in CLL. [23] [24] [25] [26] [27] [28] 56 In summary, the preclinical activity of IPI-145, an inhibitor of p110δ and p110γ isoforms of PI3K in CLL is supported by the data generated. As p110γ is also predominantly expressed in T cells, 57 additional studies of IPI-145 on the function of T-cell subsets are warranted. T cells have been reported to promote the survival and proliferation of CLL cells, 58, 59 therefore, abrogation of their ability to provide support for CLL cells through the inhibition of T-cell activation or migration could potentially provide a therapeutic benefit for CLL patients treated with IPI-145. The activity of IPI-145 is selective to primary CLL cells as the survival of normal PBMCs, B cells or T cells are unaffected ( Figure 7) . As p110δ is critical for CXCL13-driven migration of B cells 60 and p110γ is important in the CXCL12-mediated migration of T cells, 61 the p110γ inhibition with IPI-145 may have effect on specific T-cell subsets within tumor microenvironment. The encouraging preclinical and clinical data with IPI-145 support the continued clinical evaluation of dual inhibition of p110δ and p110γ isoforms in CLL, and indicate that p110γ as may be another important target in this indolent disease. 
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